SUZHOU, China, Nov. 28, 2024 -- TenNor Therapeutics announced that it has entered an exclusive commercial partnership agreement with Grand Life Sciences (“GLS”) Group for rifasutenizol (TNP-2198) for the treatment of H. pylori infection. Under the agreement, TenNor licenses GLS’s wholly-owned subsidiary, Hangzhou Grand Biologic Pharmaceutical INC. ("Hangzhou Grand"), to exclusively commercialize and promote rifasutenizol in mainland China, Hong Kong and Macau.

SUZHOU, China, Nov. 18, 2024 -- TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical trial of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The study met its primary endpoints, showing multiple advantages of rifasutenizol regimen compared with bismuth-containing quadruple therapy (BQT), the current standard of care.

October 18, 2024, Los Angels USA – Today, TenNor Therapeutics and its partners presented a series of research results on TNP-2092 (rifaquizinone) for the treatment of implantable medical device infections at the IDWeek 2024.

SUZHOU, China, Oct. 16, 2024 -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than 300 million RMB. New investor AMR Action Fund joined Zhongshan Venture Capital and other existing investors in the round. The proceeds will be used to support the development and to seek regulatory approval in China of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years.

July 2, 2024 – TenNor will present a series of posters on its investigational new drug rifaquizinone (TNP-2092) for the treatment of medical device infections at IDWeek 2024 to be held in Los Angeles, USA from October 16 to 20, 2024.

May 30, 2024 - May 28th is The International Day of Action for Women’s Healthcare to raise awareness for diseases and conditions that affect women’s physical and emotional health. The Journal of Medicinal Chemistry published a special Collection and showcased 17 articles that address the ongoing research dedicated to the unmet medical needs in women’s healthcare. TenNor’s article “Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens” was chosen for inclusion in the Collection and recognized in advancing research in women’s healthcare.

Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.

December 28, 2023 – The National Medical Products Administration (NMPA) approved TNP-2092 ointment to conduct a Phase I/II clinical trial for the treatment of diabetic foot infection (DFI).